The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

B Capital, a global multi-stage investment firm, today announced that it has been selected as a registered venture capital firm under the Government of Japan’s Agency for Medical Research and ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

This is Gilead's third acquisition this year alone. At this point, M&A is less about growth and more about survival for the ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...

US drugmaker Eli Lilly has signed a $2bn deal with a Hong Kong-listed company that uses AI for drug discovery, highlighting ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter: Abivax: ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company' or 'Jyong Biotech'), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...

The Trump administration dropped its fiscal 2027 budget request Friday, and the massive document release includes some ...